



**SZABO
SCANDIC**

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic



PRODUCT INFORMATION

Nitrofurantoin-¹³C₃

Item No. 33296

CAS Registry No.: 1217226-46-4

Formal Name: 1-[[(5-nitro-2-furanyl)methylene]amino]-2,4-imidazolidinedione-¹³C₃

MF: C₅[¹³C]₃H₆N₄O₅


FW: 241.1

Purity: ≥95%

Supplied as: A solid

Storage: -20°C

Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Nitrofurantoin-¹³C₃ is supplied as a solid. A stock solution may be made by dissolving the nitrofurantoin-¹³C₃ in the solvent of choice, which should be purged with an inert gas. Nitrofurantoin-¹³C₃ is slightly soluble in methanol and DMSO.

Description

Nitrofurantoin-¹³C₃ is intended for use as an internal standard for the quantification of nitrofurantoin (Item No. 23510) by GC- or LC-MS. Nitrofurantoin is a nitrofuran antibiotic.¹ *In vivo*, nitrofurantoin (25-100 mg/kg) reduces *E. coli* replication and abscess formation in the renal medulla of infected rats in a dose-dependent manner. It prevents kidney and bladder infection in rats following bladder inoculation with clinical isolates of *P. mirabilis*. Nitrofurantoin also prevents alkalization of urine, as well as calculi and abscess formation, in a rat model of *P. vulgaris* urinary tract infection.² Formulations containing nitrofurantoin have been used in the treatment of urinary tract infections.

References

1. Rocha, H., Da Silva Teles, E., and Barros, M. Site of action of nitrofurantoin in experimental urinary tract infection. *Appl. Microbiol.* **18**(4), 547-549 (1969).
2. Hossack, D.J.N. Proteus vulgaris urinary tract infections in rats; treatment with nitrofuran derivatives. *Br. J. Pharmacol. Chemother.* **19**(2), 306-312 (1962).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/04/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 - USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM